1. Hepatitis C Therapy: Lessons of the Last Two Decades

   • Sudeep Tanwar
   • Paul M. Trembling
   • Geoffrey M. Dusheiko

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 15 August 2012 Pages: 119 - 127

   

2. Impact of Ethnicity and Race on Treatment Response: Past, Present and Future

   • Maribel Rodríguez-Torres
   • Deana Hallman

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 15 July 2012 Pages: 128 - 135

   

3. IL28B: Current and Future Use

   • S. G. Chen Yi Mei
   • P. V. Desmond
   • A. J. Thompson

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 28 July 2012 Pages: 136 - 145

4. Non-interferon Therapies for Hepatitis C

   • Fernando E. Membreno
   • Eric J. Lawitz

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 25 July 2012 Pages: 146 - 152

5. Cyclophilin Inhibitors

   • Robert Flisiak
   • Anna Parfieniuk-Kowerda

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 05 July 2012 Pages: 153 - 159

6. Telaprevir and Boceprevir: The Future Is Now

   • Beatriz Calle Serrano
   • Michael P. Manns

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 01 September 2012 Pages: 160 - 171

7. Second Generation Protease Inhibitors and Nucleotide Inhibitors

   • Syed-Mohammad Jafri
   • Stuart C. Gordon

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 20 July 2012 Pages: 172 - 180

8. NS5A Inhibitors

   • Christopher O’Brien
   • Nicholas Agresti

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 10 August 2012 Pages: 181 - 187

9. Resistance to Direct-Acting Antivirals

   • Jean-Michel Pawlotsky

   Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 02 August 2012 Pages: 188 - 194